Needham & Company Starts Selecta Biosciences (SELB) at Buy

Needham & Company initiates coverage on recent IPO Selecta Biosciences (NASDAQ: SELB) with a Buy rating and a price target of $28.00.

Analyst Chad Messer commented, "Selecta develops Synthetic Vaccine Particles (SVPs) that can be used to enhance or diminish the immune system's response to a given antigen. The focus of the company is reducing anti-drug antibodies (ADAs) and other forms of immunogenicity that are a limitation on many biologic therapies. Selecta's lead program, SEL-212, has demonstrated clinical proof of concept in gout and will enter Phase II this summer. Selecta also plans on using its SVPs to address the limitations of ADAs in gene therapy. Selecta is researching other uses for its SVP platform in autoimmune disease, allergies, and vaccines in collaboration with various partners including Sanofi. We believe there is broad applicability of SVP technology and view Selecta's internal focus on immunogenicity as a differentiated strategy de-risked by human proof of concept."

For an analyst ratings summary and ratings history on Selecta Biosciences click here. For more ratings news on Selecta Biosciences click here.

Shares of Selecta Biosciences closed at $14.00 yesterday.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• Impinj Inc (PI) PT Raised to $160 at Needham
• Merck (MRK) PT Raised to $143 at Truist Securities